Updates in antifungal susceptibility testing of filamentous fungi

Current Fungal Infection Reports

Volumn 3, Issue 3, 2009, Pages 133-141

  Espinel Ingroff, Ana ^a   Canton, Emilia ^a   Peman, Javier ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; AMPHOTERICIN B; ANTIFUNGAL AGENT; ECHINOCANDIN; ITRACONAZOLE; TRIAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; BROTH DILUTION; DISK DIFFUSION; FUNGICIDAL ACTIVITY; FUNGUS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DYNAMICS; MOULD; NONHUMAN; REVIEW;

EID: 77953533265     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-009-0017-7     Document Type: Review

References (51)

1. Espinel-Ingroff A: In vitro susceptibility testing: when, where, and what to use. J Invasive Fungal Infect 2008, 2:52-61. This detailed review describes reference and alternative approaches for susceptibility testing of yeasts and molds; their clinical relevance or lack thereof is also discussed.
2. Garcia-Vidal C, Upton A, Kirby KA, Marr KA: Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008, 47:1041-1050. A recent report of the epidemiology of mold infections is provided in this article.
3. Neofytos D, Horn D, Anaissie E, et al.: Epidemiology and outcome of invasive fungal infections in adult hematopoietic stem cell transplant recipients: analysis of multicenter PATH Alliance Registry. Clin Infect Dis 2009, 48:265-273. This article provides a recent report of the epidemiology and the outcome of mold infections in this group of patients.
4. Snelders E, van der Lee HA, Kuijpers J, et al.: Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008, 5:1629-1637. This study reports on the emergence and prevalence of itraconazole resistance in A. fumigatus during the past 14 years in The Netherlands. Itraconazole resistance was associated with reduced susceptibility to other triazoles.
5. Pfaller MA, Messer SA, Boyken L, et al.: In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus spp. J Clin Microbiol 2008, 46:2568-2572. This article provides the incidence of triazole resistance in various Aspergillus spp isolates.
6. Krishnan-Natesan S, Chandrasekar PH, Alangaden GJ, Manavathu EK: Molecular characterisation of cyp51A and cyp51B genes coding for P450 14alpha-lanosterol demethylase A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus. Int J Antimicrob Agents 2008, 32:519-524. This article reports on the molecular characterization of voriconazole resistance in A. flavus.
7. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, et al.: A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007, 51:1897-1904. This article describes a new molecular azole resistance mechanism in A. fumigatus.
8. Rocha EM, Garcia-Effron G, Park S, Perlin DS: A ser67Pro substitution in Fk51p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 2007, 51:4174-4176. A similar mutation to that associated with echinocandin resistance in Candida albicans was also associated with resistance to echinocandins in A. fumigatus.
9. Blum G, Perkhofer S, Haas H, et al.: Potential basis for amphotericin B resistance in Aspergillus terreus. Antimicrob Agents Chemother 2008, 52:1553-1555. This article investigated the basis for the intrinsic resistance of A. terreus to amphotericin B. The authors concluded that high catalase levels may be the cause of resistance.
10. Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, et al.: Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 2008, 52:2468-2472. This article provides the epidemiological cutoffs for A. fumigatus and four triazoles by the EUCAST method; the cutoff was lower for posaconazole. Triazole cross-resistance was associated with specific cyp51A mutations.
11. Pfaller MA, Diekema DJ, Ghannoum MA, et al.: Wild type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standard Institute broth microdilution methods. 2009 (in press). This article provides the epidemiological cutoffs for A. fumigatus and four triazoles by the CLSI method; the cutoffs were the same as those previously reported by the EUCAST method.
12. Espinel-Ingroff A: Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi. Rev Iberoam Micol 2008, 25:99-104. This paper provides a comprehensive review of the literature (2005-2008) regarding molecular mechanisms of resistance and their correlation with in vitro and in vivo results for yeasts and molds.
13. Espinel-Ingroff A, Bartlett M, Bowden, R, et al.: Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol 1997, 35:139-143. (Pubitemid 26422642)
14. Espinel-Ingroff A, Bartlett M, Chaturvedi V, et al.: Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. Antimicrob Agents Chemother 2001, 45:1828-1835. (Pubitemid 32466356)
15. Espinel-Ingroff A, Chaturvedi V, Fothergill A, Rinaldi MG: Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J Clin Microbiol 2002, 40:3776-3781.
16. Espinel-Ingroff A, Dawson K, Pfaller MA, et al.: Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 1995, 39:314-319.
17. Clinical and Laboratory Standards Institute/National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved Standard, edn 2; Document M38-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2008. This recently published CLSI document describes in detail the new testing guidelines for susceptibility testing of molds, including those for the echinocandins.
18. Espinel-Ingroff A, Arthington-Skaggs B, Iqbal N, et al.: Muticenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B and caspofungin. J Clin Microbiol 2007, 45:1811-1820. The guidelines for testing molds by the disk diffusion method were identified during this CLSI collaborative study. In vitro MIC and MEC breakpoints as well interpretive zone diameters were assigned.
19. Espinel-Ingroff A: Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J Clin Microbiol 2003, 41:403-409.
20. Espinel-Ingroff A, Fothergill A, Ghannoum M, et al.: Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds. J Clin Microbiol 2007, 45:2180-2182. This article describes the first collaborative study conducted for the selection of quality control isolates and establishment of MEC limits for mold testing with anidulafungin.
21. Odds FC, Motyl M, Andrade R, et al.: Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol 2004, 42:3475-3482. (Pubitemid 39045669)
22. Almyroudis NG, Sutton DA, Fothergill AW, et al.: In vitro susceptibilities of 217 clinical isolates of Zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007, 51:2587-2590. This paper provides in vitro data for a large number of mucoraceous isolates.
23. Espinel-Ingroff A, Fothergill, A, Ghannoum, M, et al.: Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M38-A document) of amphotericin B, itraconazole, posaconazole and voriconazole. J Clin Microbiol 2005, 43:5243-5246. (Pubitemid 41484032)
24. Petraitis V, Petraitiene R, Groll AH, et al.: Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002, 46:1857-1869. (Pubitemid 34535208)
25. Castiglioni B, Sutton DA, Rinaldi MG, et al.: Pseudallescheria boydii (anamorph Scedosporium apiospermum) infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine 2002, 81:333-348.
26. Lass-Florl C, Kofler G, Kropshofer G, et al.: In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 1998, 42:497-502. (Pubitemid 28473010)
27. Novicki TJ, LaFe K, Bui L, et al.: Genetic diversity among clinical isolates of Acremonium strictum determined during an investigation of a fatal mycosis. J Clin Microbiol 2003, 41:2623-2628. (Pubitemid 36712476)
28. Denning DW, Radford SA, Oakley KL, et al.: Correlation between in vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997, 40:401-414. (Pubitemid 27437961)
29. Espinel-Ingroff A, Johnson E, Hockey H, Troke PF: Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in voriconazole phase III clinical studies. J Antimicrob Chemother 2008, 61:616-620. This is the first report of the data obtained for all filamentous fungi that were recovered during voriconazole phase 3 clinical trials. The clinical response to voriconazole therapy during these studies is described, as well as the in vitro susceptibilities of these isolates to three other antifungal agents.
30. Troke P, Aguirrebengoa K, Arteaga C, et al.: Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008, 52:1743-1750. This is a report of relevant data regarding the clinical response to voriconazole therapy for a large number of patients with scedosporiosis.
31. Sun QN, Najvar LK, Bocanegra R, et al.: In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother 2002, 46:2310-2312. (Pubitemid 34665939)
32. Walsh TJ, Raad I, Patterson TF, et al.: Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007, 44:2-12. In this study, posaconazole plasma concentrations correlated with patient outcome; high plasma concentrations were associated with higher response to posaconazole therapy for invasive aspergillosis.
33. Clinical and Laboratory Standards Institute/National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard, edn 3; Document M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2008. This CLSI document describes in detail the new guidelines for testing yeasts, including those for the echinocandins. The newly established echinocandin-susceptible breakpoint for Candida spp is also described.
34. Castro C, Serrano MC, Florez B, et al.: Comparison of sensititre YeastOne colorimetric antifungal panel with a modified NCCLS M38-A method to determine the activity of voriconazole against clinical isolates of Aspergillus spp. J Clin Microbiol 2004, 42:4358-4360. (Pubitemid 39296177)
35. Linares MJ, Charriel G, Solis F, et al.: Susceptibility of filamentous fungi to voriconazole tested by two microdilution methods. J Clin Microbiol 2005, 43:250-253. (Pubitemid 40096308)
36. Martin-Mazuelos E, Peman J, Valverde A, et al.: Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp. J Antimicrob Chemother 2003, 52:365-370. (Pubitemid 37120713)
37. Espinel-Ingroff A: Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing Zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B. J Clin Microbiol 2006, 44:3616-3622. This paper describes the comparison of three commercial assays (Etest, YeastOne, and Neo-Sensitabs) with reference broth dilution and disk diffusion methods for testing posaconazole and amphotericin B for a large number of yeasts, including Cryptococcus neoformans, Aspergillus spp, and mucoraceous isolates.
38. Torres-Narbona M, Guinea J, Martinez-Alarcon J, et al.: In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole and voriconazole against 45 clinical isolates of Zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne and Etest. Antimicrob Agents Chemother 2007, 51:1126-1129. (Pubitemid 46355313)
39. Alvarado-Ramirez E, Torres-Rodriguez JM: In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods. Antimicrob Agents Chemother 2007, 51:2420-2423. (Pubitemid 47047319)
40. Clinical and Laboratory Standards Institute/National Committee for Clinical Laboratory Standards: Method for antifungal disk diffusion susceptibility testing of yeasts: approved guideline. Document M44-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2004.
41. Espinel-Ingroff A, Canton E: Comparison of Neo-Sensitabs tablet diffusion assay with CLSI broth microdilution M38-A and disk diffusion methods for testing susceptibility of filamentous fungi with amphotericin B, caspofungin, itraconazole, posaconazole and voriconazole. J Clin Microbiol 2008, 46:1793-1803. The first comparison of the Neo-Sensitabs tablet method with both disk and broth dilution reference methods for mold testing is provided in this article.
42. Espinel-Ingroff A: Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi. J Clin Microbiol 2001, 39:1360-1367.
43. Espinel-Ingroff A, Rezusta A: E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method. J Clin Microbiol 2002, 40:2101-2107. (Pubitemid 34596392)
44. Pfaller JB, Messer SA, Hollis RJ, et al.: In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs. J Clin Microbiol 2003, 41:1126-1129. (Pubitemid 36307117)
45. Serrano MC, Ramirez M, Morilla D, et al.: A comparative study of the disc diffusion method with the broth microdilution and Etest methods for voriconazole susceptibility testing of Aspergillus spp. J Antimicrob Chemother 2004, 53:739-742. (Pubitemid 38678507)
46. Messer SA, Diekema DJ, Hollis RJ, et al.: Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi. J Clin Microbiol 2007, 45:1322-1324. (Pubitemid 46626507)
47. Arendrup MC, Perkhofer S, Howard SJ, et al.: Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob Agents Chemother 2008, 52:3504-3511.
48. Espinel-Ingroff A, Chaturvedi V, Fothergill A, Rinaldi MG: Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol 2002, 40:3204-3208. (Pubitemid 34977429)
49. Meletiadis J, Antachopoulos C, Stergiopoulou T, et al.: Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species by microbroth methodology. Antimicrob Agents Chemother 2007, 51:3329-3337. This article reports a novel and shorter method for determining the fungicidal susceptibilities of Aspergillus to two antifungal agents.
50. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST): EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect 2008, 14:982-984. This article provides EUCAST testing guidelines for mold testing.
51. Garcia-Effron G, Dilger A, Alcazar-Fuoli L, et al.: Rapid detection of triazole antifungal resistance in Aspergillus fumigatus. J Clin Microbiol 2008, 46:1200-1206. This is the first study to evaluate a molecular method for the rapid detection of triazole resistance.